Bayer to present new Phase III data for the investigational low-dose MRI contrast agent gadoquatrane at ECR 2026, featuring a 60% reduction in gadolinium dose.
stellanews.life/technology/8...
#MRI #Radiology #Bayer #ECR2026 #Gadoquatrane #Phase3 #MedicalImaging #ContrastAgent